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httpcense.Abstract Repeated thoracentesis may cause pleural inﬂammation and induce local release of pro-
infammatory cytokine as tumor necrosis factor-a (TNF-a) which may subsequently enhance the
release of plasminogen activator inhibitor-1 (PAI-1) and lead to ﬁbrin formation in malignant effu-
sion. The presence of ﬁbrin strands after repeated thoracentesis may be of considerable value in pre-
dicting the success of subsequent pleurodesis in patients with malignant pleural effusions (MPEs).
So, the aim of this work is to study the impact of repeated thoracentesis on the outcome of chemical
pleurodesis in MPE.
Patients and methods: This is a retrospective study included 116 patients with MPE, they were
diagnosed ﬁnally by pleural ﬂuid (PF) cytology and/or either computed tomography (CT)-guided
biopsy or tissue biopsy (Abram’s or thoracoscopic biopsy). These patients were admitted and sub-
jected to the following: a) Pleural tapping and the aspirated ﬂuid was sent for chemical, cytological
and bacteriological examinations for determination of the inclusion criteria, (b) Tube thoracostomy
insertion, (c) Pleurodesis, and assessment of the response to pleurodesis was done once after 30 days
and another after 60 days.
Results: Regarding pleurodesis success or failure in this work, there was statistically highly sig-
niﬁcant decrease in the duration of chest tube before pleurodesis in patients with successful pleurod-
esis than that in patients with failed one. But, statistically non-signiﬁcant decrease was observed in
the duration of chest tube after pleurodesis in patients with successful pleurodesis than that in
patients with failed one. There was statistically signiﬁcant negative correlation between the number
of pleural ﬂuid (PF) aspiration and the duration of chest tube after pleurodesis and statistically non-
signiﬁcant negative correlation between the number of PF aspiration and the duration of chest tube
before pleurodesis. Also, to predict the success of the pleurodesis, after 30 days of pleurodesis with
cut-point of PF aspiration number >7 times, sensitivity and speciﬁcity were 75.3% and 65.7%3477882.
hoo.com (A. Shaker).
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392 A. Salah et al.respectively and after 60 days of pleurodesis, also, at cut-point of PF aspiration number >7 times,
sensitivity of 80.3% was higher than that after 30 days of pleurodesis and speciﬁcity of 64.4% which
was near that after 30 days of pleurodesis.
Conclusion: Repeated thoracentesis may be of considerable value in predicting the success of
subsequent chemical pleurodesis in MPE. Repeated thoracentesis of MPE >7 times has good sen-
sitivity, but low speciﬁcity in predicting success of subsequent chemical pleurodesis. Measurement
of PF glucose levels and PF cytology provide information about the outcome of chemical pleurod-
esis in MPE.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Pleurodesis aims to achieve a symphysis between parietal and
visceral pleural surfaces in order to prevent accumulation of
ﬂuid or air in the pleural space. Its major indications are
MPE and pneumothorax. The cellular and biochemical mech-
anisms involved in pleurodesis may be speciﬁc to the agent
used however, they may all follow a common ﬁnal pathway
leading to activation of the pleural coagulation cascade, the
appearance of ﬁbrin networks and the proliferation of ﬁbro-
blasts. The details of these mechanisms are still unclear and
need to be further elaborated [1].
Repeated thoracentesis may cause pleural inﬂammation
and induce local release of proinfammatory cytokine as
TNF-a which may subsequently enhance the release of PAI-
1 and lead to ﬁbrin formation in malignant effusion. The pres-
ence of ﬁbrin strands after repeated thoracentesis may be of
considerable value in predicting the success of subsequent
pleurodesis in patients with MPEs [2]. So, the aim of this work
is to study the impact of repeated thoracentesis on the outcome
of chemical pleurodesis in malignant pleural effusion.Patients and methods
This is a retrospective study included 116 patients with MPE
out of 175 patients for whom pleurodesis was done in the per-
iod from 2001 until 2009.The patients were admitted at Chest
and Cardiothoracic Surgery Departments, Zagazig University
Hospitals, they were 82 males and 34 females with a mean age
of 55.21 ± 9.02. They were diagnosed ﬁnally by PF cytology
and/or CT-guided biopsy or tissue biopsy (Abram’s or tho-
racoscopic biopsy). Those 116 patients were enrolled in the
study as their data were completely recorded in their ﬁles
including the number of thoracentesis done for them before
pleurodesis.
The data retrieved from the patient’s ﬁles were recorded
including:
1. PF biochemical parameters [protein, lactate dehydrogenase
(LDH), glucose, pH and white blood cells count (WBCs)].
2. Type of malignancy.
3. Number and amount of thoracentesis done.
4. Chemical substance used for pleurodesis.
5. Techniques of pleurodesis (tube thoracostomy (ICT) or
thoracoscope).
6. Duration of chest tube before and after instillation of the
chemical agent.
7. Result of pleurodesis.The patients were candidates for pleurodesis according to the
following criteria
Inclusion criteria [3]
1- Massive or fast collecting pleural effusion after drainage,
which requires frequent thoracentesis (< 3 days).
2- Subjective improvement of dyspnea following
thoracentesis.
3- Re-expansion of the lung after drainage.
4- Life expectancy >6 months
5- PF pH> 7.2.Exclusion criteria [4]
1- Atelectasis due to endobronchial obstruction.
2- PF pH< 7.2.
3- Prior intrapleural therapy in the previous two weeks.
4- Signiﬁcant irradiation to the affected hemithorax.These patients were admitted and subjected to the following
1- Thorough medical history stressing on smoking history
and history of occupational exposure.
2- Full clinical examination both general and local (chest)
examination.
3- Routine investigations to evaluate the patient general
condition (complete blood count, erythrocyte sedimen-
tation rate, liver and kidney function tests).
4- Plain chest X-ray (CXR) (postero-anterior and lateral
views).
5- Pleural tapping and the aspirated ﬂuid was sent for
chemical, cytological and bacteriological examinations
for determination of the inclusion criteria.
6- Tube thoracostomy insertion [5]:
The patient was premedicated with 0.6 ml atropine sulphate
given intramuscularly 30 min prior to the procedure. Proper
position with the patient supine, skin disinfection and anesthe-
sia was inﬁltrated with 10 CC xylocaine 2% followed by aspi-
ration to conﬁrm the presence of the ﬂuid. An incision about
2 cm was done in the ﬁfth or sixth intercostal space in the
midaxillary line. The incision was made at the upper border
of the rib below and parallel to the rib. A large bore chest tube
(28–30 French) was used to allow adequate drainage. After
appropriate positioning, ﬁxation of the tube was done by the
Table 1 Demographic data of the studied patients.
Characteristic Value
Age (years) 55.21 ± 9.02
Sex
Male, no (%) 82 (70.7%)
Female, no (%) 34 (29.3%)
Type of malignancy, no (%)
Bronchogenic carcinoma 38 (32.8%)
Lymphoma 30 (25.9%)
Metastatic carcinoma 40 (34.4%)
Mesothelioma 8 (6.9%)
Diagnosis by
CT-guided biopsy, no (%) 6 (5.2%)
Tissue biopsy, no (%) 110 (94.8%)
PF analysis (M±SD)
pH 7.31 ± 0.063
Glucose (mg/dl) 74.4 ± 16.07
Protein (g/dl) 4.08 ± 0.55
LDH (U/L) 1734.2 ± 433.2
WBCs (Cells /mm3) 668.5 ± 174.8
Positive cytology, no (%) 53 (45.7%)
The impact of repeated thoracentesis 393suture. The chest tube was connected to underwater seal to al-
low slow drainage of the effusion. When the amount of effu-
sion became less than 100 ml/24 h and chest X-ray showed
complete lung expansion and there was no evidence of bron-
chopleural ﬁstula, pleurodesis was carried out.
1- 7- Pleurodesis.
0.6 ml atropine sulfate intramuscular was given 30 minutes
before the procedure. 50 ml normal saline solution containing
2 mg/kg lidocaine was infused through the chest tube. The pa-
tient was advised to lie on either side front and back for 10
minutes to allow contact of the lidocaine to the whole pleural
surface (as possible). The chemical agent (doxycycline, iodop-
ovidone, talc slurry or bleomycin) was instilled through the
chest tube. The chest tube was clamped immediately after
injection of the chemical agent for 2 h after which it was let
open for drainage [6].
Follow up chest radiographs were done every 24 h till re-
moval of the tube. When the amount of the effusion became
less than 100 ml/24 h the tube was removed. The patient was
discharged and was followed up clinically and radiologically
by chest X-ray weekly for one month and monthly for two
months [3].
Assessment of the response [7]
The effectiveness of pleurodesis was considered as follows:
1- Complete response: total resolution of pleural effusion
with no reaccumulation within two months.
2- No response: reaccumulation of pleural effusion within
two months.
Statistical analysis
Statistical analysis was performed with the SPSS statistical
software package (SPSS Inc., Chicago, IL).
Data presented by mean ± SD for quantitative continuous
data was calculated by one way analysis for variance (F test).
Qualitative data was presented by number and percentage
and association was tested by Chi-square test.
Pearson Chi-square test was used for qualitative data and
Fisher Exact test was recommended when expected cell is less
than ﬁve. P-value <0.05 is considered signiﬁcant.
Correlation coefﬁcient (r) were calculated for testing associ-
ation between quantitative variables. P-value <0.05 is consid-
ered signiﬁcant.
Receiver Operating Characteristic (ROC) curve was used
for predicting cut-point of the number of PF aspiration for
successful pleurodesis and area under the curve (AUC), 95%
conﬁdence interval (CI) were presented, sensitivity, speciﬁcity,
positive predictive value (PPV), negative predictive value
(NPV) and Kappa measurement were calculated. P-value
<0.05 is considered signiﬁcant.
Results
Table 1 showed the demographic data of the patients enrolled
in this study. The mean age of patients was 55.21 ± 9.02, 82(70.7%) males and 34 (29.3%) females. Fifty three (45.7%) pa-
tients had positive cytology of pleural ﬂuid.
Table 2 showed statistically non-signiﬁcant (P> 0.05) neg-
ative correlations between the number of PF aspiration and
each of pH, glucose and protein and statistically non-signiﬁ-
cant (P> 0.05) positive correlations between the number of
PF aspiration and both LDH and total leucocytic count
(TLC).
Figs. 1 and 2 showed a receiver operating characteristic
(ROC) analysis in which sensitivity was calculated with those
patients who showed successful pleurodesis once after 30 days
and another after 60 days of the procedure. The area under
curve (AUC), PPV, NPV, sensitivity and speciﬁcity, for cut-
point of the number of PF aspiration at which the pleurodesis
succeeded, were calculated in Tables 3 and 4. After 30 days of
pleurodesis, with cut-point of PF aspiration number >7 times,
sensitivity and speciﬁcity were 75.3% and 65.7%, respectively
with PPV and NPV were 83.6% and 53.5% respectively
(P= 0.0001). After 60 days of pleurodesis, also at cut-point
of PF aspiration number >7 times, sensitivity of 80.3% was
higher than that after 30 days of pleurodesis and speciﬁcity
of 64.4% which is near that after 30 days of pleurodesis with
PPV and NPV were 78.1% and 67.4%, respectively (P=
0.0001).
Table 5 showed statistically highly signiﬁcant increase
(P= 0.003) in the success rate of pleurodesis using chemical
sclerosing agent than that of pleurodesis without using any
chemical agent.
Table 6 showed statistically signiﬁcant (P= 0.018) negative
correlation between the number of PF aspiration and the dura-
tion of chest tube after the pleurodesis but there was statisti-
cally non-signiﬁcant negative correlation between the number
of PF aspiration and the duration of chest tube before pleurod-
esis (P= 0.17).
Table 7 showed statistically highly signiﬁcant decrease
(P= 0.0001) in PF glucose level and non-signiﬁcant (P=
0.67) decrease in PF pH in patients with failed pleurodesis than
Table 2 Correlation between PF analysis parameters and the number of PF aspiration in all studied patients.
Number of PF aspiration pH LDH (U/L) Glucose (mg/dl) Protein (g/dl) WBCs (Cell/mm3)
r-value 0.126 0.34 0.033 0.106 0.137
P-value 0.176 0.717 0.728 0.256 0.143
Figure 1 ROC curve for prediction of success of pleurodesis
after 30 days.
Figure 2 ROC curve for prediction of success of pleurodesis
after 60 days.
Table 3 Cut-point of the number of PF aspiration in patients
with successful pleurodesis after 30 days and after 60 days of
the procedure.
After 30 days After 60 days
Cut-point of the number
of PF aspiration
>7 >7
AUC 0.75 0.76
CI 95% 0.65–0.85 0.66–0.85
394 A. Salah et al.those in patients with successful one. There was statistically
highly signiﬁcant increase (P= 0.001) in the presence ofpositive PF cytology in patients with failed pleurodesis than
that in patients with successful one. Also, there was statistically
highly signiﬁcant increase in the duration of chest tube before
pleurodesis in patients with failed pleurodesis than that in pa-
tients with successful one (P= 0.001). Statistically signiﬁcant
increase was observed in the number of PF aspiration
(P= 0.0001) and total amount aspirated (P= 0.02) in the pa-
tients with successful pleurodesis than that in patients with
failed one. There were statistically non-signiﬁcant differences
between patients with successful pleurodesis and those with
failed one as regards age, sex, type of malignancy and the
duration of the chest tube after pleurodesis.
Discussion
MPEs frequently cause morbidity, and treatment options are
directed at rapid and effective relief of symptoms with the least
discomfort, inconvenience and cost [8].
Once a patient develops MPE, mechanical drainage relieves
pulmonary compression and dyspnea. Optimal treatment
methods are controversial and they include multiple and repet-
itive thoracentesis alone, tube thoracostomy with or without
sclerosis, video-assisted thoracic surgery (VATS) for optimal
drainage and lung expansion with talc pleurodesis [9], outpa-
tient drainage using a variety of small tubes or catheters with
or without sclerosis or pleuroperitoneal shunts or other drain-
age devices [10].
Patients with symptomatic effusions may beneﬁt from pleu-
rodesis to relieve dyspnea and to prevent the reaccumulation
of pleural ﬂuid. Pleurodesis includes mechanical irritation of
the pleural membranes or intrapleural instillation of chemical
agents to induce pleural inﬂammation [11]. Unfortunately,
pleurodesis attempts fail in 10–40% of patients with recurrence
of PF and dyspnea [12]. So the aim of this study is to evaluate
the impact of repeated thoracentesis on the outcome of chem-
ical pleurodesis in MPE.
In our study, regarding PF analysis, there were statistically
non-signiﬁcant correlations between the number of PF aspira-
tion and PF pH and glucose levels (P= 0.176) and
(P= 0.728), respectively (Table 2). Also, there was statistically
non-signiﬁcant decrease in PF pH (P= 0.67) in patients with
failed pleurodesis than that in patients with successful one but
Table 4 Sensitivity, speciﬁcity, PPV and NPV at cut-point of >7 times of PF aspiration in patients with successful pleurodesis after
30 days and after 60 days of the procedure.
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Kappa P-value
After 30 days 75.3 65.7 83.6 53.5 0.385 0.0001
After 60 days 80.3 64.4 78.1 67.4 0.451 0.0001
Table 5 Comparison between the success rate of pleurodesis using chemical agent (regardless its type) and without using chemical
agent.
Parameter Pleurodesis using chemical agent (n= 101) Pleurodesis without using chemical agent (n= 15) v2 P-value
Success rate of pleurodesis 67 (66.33%) 4 (26.7%) 8.66 0.003
Table 6 Correlation between the number of PF aspiration
and the duration of chest tube before and after 30 days of
pleurodesis in all studied patients.
Parameter Number of PF aspiration
R P-value
Duration of chest tube:
Before pleurodesis 128 0.17
After pleurodesis 219 0.018
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level (P= 0.0001) in patients with failed pleurodesis than that
in patients with successful one (Table 7).
PF pH has only modest discriminative properties for identi-
fying patients who will experience symptomatic failure of pleu-
rodesis. PF pH didn’t have a greater predictive accuracy when
compared to glucose or LDH for predicting failure [13]. TheTable 7 Comparison between patients with successful pleurodesis a
PF analysis, the duration of chest tube before and after 60 days of ple
and the presence of complications after pleurodesis.
Parameter Successful group (n
Age (years) 55.31 ± 8.52
Sex:
Male, no (%) 50 (61%)
Female, no (%) 21 (61.8%)
Type of malignancy, no (%)
Bronchogenic carcinoma 24 (63.2%)
Lymphoma 21 (70%)
Metastatic carcinoma 23 (57.5%)
Mesothelioma 3 (37.5%)
PF analysis (M± SD)
pH 7.33 ± 0.057
Glucose 79.33 ± 15.66
Positive cytology, no (%) 14 (26.4%)
Duration of chest tube (days)
Before pleurodesis 7.23 ± 1.58
After pleurodesis 3.75 ± 1.34
Number of PF aspiration (M±SD) 8.67 ± 1.69
Total amount aspirated (L) (M±SD) 8.0 ± 2.2cause in this study may be due to the fact that all patients with
pH < 7.2 were excluded from performing pleurodesis.
There is impaired glucose transfer from blood to PF and
from PF to blood in patients with low-pH but not normal-
pH MPE. The glucose that enters the pleural space appears
to be metabolized at a rate similar to that of normal-pH malig-
nant effusions by malignant cells, free in the PF and in the
pleural tissues, to the end-products, CO2 and lactic acid. Due
to abnormal pleura in patients with low-pH effusions, the rate
of transport of CO2 and lactic acid out of the pleural space is
slowed, and accumulation occurs, resulting in a decrease in PF
pH. Furthermore, oxygen transport into low-pH malignant
effusions is abnormal resulting in a low-O2 environment, fur-
ther promoting increased pleural lactic acid concentrations
[14].
Rodriguez-Panadero and mejias [15] reported that the esti-
mated PF volume had a greater inﬂuence on glucose levels
than on pH values and this ﬁnding may be due to an increase
of glucose consumption by ﬂuid cells, whether they are or are
not malignant.nd those with failed one as regards age, sex, type of malignancy,
urodesis, the number of PF aspiration,total amount aspirated (L)
= 71) Failure group (n= 45) P-value
55.04 ± 9.84 0.87
32 (39%) 0.937
13 (38.2%)
14 (36.8%) 0.76
9 (30%) 0.25
17 (42.5%) 0.55
5 (62.5%) 0.25
7.29 ± 0.372 0.67
63.53 ± 16.85 0.0001
39 (73.6%) 0.001
8.37 ± 1.92 0.001
3.88 ± 1.28 0.39
6.73 ± 2.03 0.0001
6.9 ± 3.1 0.02
396 A. Salah et al.Burrows et al. [16] found no correlation between pleural
ﬂuid pH or PF glucose levels with survival.
Regarding pleurodesis success or failure in this work, there
was statistically highly signiﬁcant decrease in the duration of
chest tube before pleurodesis in patients with successful pleu-
rodesis than that in patients with failed one (P= 0.001) (Table
7). But, statistically non-signiﬁcant decrease was observed in
the duration of chest tube after pleurodesis in patients with
successful pleurodesis than that in patients with failed one
(P= 0.39) (Table 7). There was statistically signiﬁcant nega-
tive correlation (P= 0.018) between the number of PF aspira-
tion and the duration of chest tube after pleurodesis and
statistically non-signiﬁcant negative correlation (P= 0.17) be-
tween the number of PF aspiration and the duration of chest
tube before pleurodesis (Table 6).
In our study, there was statistically highly signiﬁcant in-
crease in success rate of pleurodesis in patients in whom pleu-
rodesis was done using chemical sclerosing agent than that in
patients in whom pleurodesis was done without using chemical
agent (P= 0.003) (Table 5).
Also, to predict the success of the pleurodesis after 30 days
and after 60 days, a receiver operating characteristic analysis
was performed (Figs. 1 and 2). After 30 days of pleurodesis,
with cut-point of PF aspiration number >7 times, sensitivity
and speciﬁcity were 75.3% and 65.7%, respectively with PPV
and NPV were 83.6% and 53.5%, respectively (P= 0.0001)
(Table 4). After 60 days of pleurodesis, also at cut-point of
PF aspiration number >7 times, sensitivity of 80.3% was
higher than that after 30 days of pleurodesis and speciﬁcity
of 64.4% which is near that after 30 days of pleurodesis with
PPV and NPV were 78.1% and 67.4% respectively (P=
0.0001) (Table 4).
Chung et al. [2] demonstrated that PF values of TNF-a,
PAI-1, interleukin-8 (IL-8) and neutrophils increased signiﬁ-
cantly during repeated thoracentesis, and ﬁbrin strands devel-
oped in pleural ﬂuid were shown on chest ultrasonography.
The ﬁbrinolytic activity is enhanced in malignant pleural
effusion as evidenced by higher cells of tissue type plasminogen
activator (tPA) in malignant effusion than in inﬂammatory
exudates. In contrast, ﬁbrinolytic activity is depressed as
shown by an increase of PAI-1 in the inﬂammatory effusions,
which may subsequently lead to ﬁbrin formation and this oc-
curs with repeated thoracentesis of MPE [17].
These ﬁndings strongly supported that the decreased ﬁbrino-
lytic activity, as evidenced by an increase of PAI-1, in malignant
effusion following repeated thoracentesis could be regulated by
TNF-a. The presence of ﬁbrin strands in malignant effusion
after repeated thoracentesis is of clinical signiﬁcance because
the successful rate of subsequent pleurodesis was signiﬁcantly
higher in the ﬁbrinous pleural effusion patients. Accordingly,
the presence of ﬁbrin strands in malignant effusion after re-
peated thoracentesis may serve as a valuable indicator for pre-
dicting the outcome of subsequent pleurodesis [2].
This explains our results, and also explains why the duration
of chest tube before and after pleurodesis in successful pleurod-
esis patients was less than that in failed pleurodesis patients.
Regarding our results of the success rate, when the pleurod-
esis was done using a chemical sclerosing agent and when it
was done spontaneously by chest tube itself without using a
chemical agent, the changes of ﬁbrinolytic activity in malig-
nant effusion after intrapleural administration of irritative
agents might be regulated by proinﬂammatory cytokines, be-cause TNF-a and interleukin-1B (IL-1B) increased markedly
in pleural ﬂuid as did PAI-1 [18]. These ﬁndings strongly sug-
gest that pleural inﬂammation may reduce ﬁbrinolytic activity
in PF via pro-inﬂammatory cytokines such as TNF-a and IL-
1B[2].
Other mechanisms, by which chemical sclerosing agents act,
are; tetracycline acts directly, in a similar fashion to the growth
factor secreted by ﬁbroblasts. It also acts indirectly by stimu-
lating pleural macrophages, which in turn activate the pleural
mesothelial cells [19]. Iodopovidone has strong oxidative and
cytotoxic properties which can induce potent inﬂammatory re-
sponse in the wall of any ﬂuid-containing structure [20] and
talc acts by the production of ﬁbroblast growth factor [21].
The chemical pleurodesis may fail and this is because of the
sclerosing agent doesn’t induce a strong enough inﬂammatory
reaction and ﬁbroplasias on pleura changed by carcinoma or
ﬁbrosis [22].
On the other hand, in our study, there were 4 patients with
successful pleurodesis, no sclerosing agents was used and pleu-
rodesis was done with chest tube drainage of ﬂuid only.
Tube drainage per se can cause pleurodesis in some cases of
MPE [23]. The mechanisms of this could be contact between
the pleural surfaces, action of the surface of the tube or the
trauma caused by the trocar [24]. Regarding PF cytology, in
our study, there was statistically highly signiﬁcant increase in
the presence of positive PF cytology in patients with failed
pleurodesis than that in patients with successful one
(P= 0.001) (Table 7).
The ﬁnding of malignant cytology in the PF examination
has been related to the grade of involvement of the pleural sur-
face by carcinoma [25].
Pleural metastasis occurs initially in the visceral pleura
from pulmonary arterial emboli or contiguous spread and sub-
sequently seeds the parietal pleura after exfoliation into the PF
or migration along performed or tumor-induced pleural adhe-
sions. Therefore, based on the pathogenesis of pleural metasta-
sis, high sensitivity from PF cytologic examination may be
found when the pH was low [22].
Light [26] found that nearly all patients in his study who
failed to achieve pleurodesis have had positive PF cytology
for malignancy, this was because PF cytology reﬂects the de-
gree of pleural inﬁltration (the degree of tumor invasion to
the pleura), leaving less healthy pleural surface available for
the chemical agent to act or to induce pleurodesis.
It was reported that PF cytology was highly correlated to
PF pH [15]. In contrary, Martinez-Moragon et al. [25] demon-
strated that patients with malignant pleural cytology did not
present a signiﬁcant different probability of response in their
study. Probably other factors that inﬂuence the percentage of
positive cytologic tests of PF (histology of the primary tumor,
number of separate specimens examined and skill of the cytol-
ogist) may explain this difference.
Other factors may be implicated to affect the success or fail-
ure of pleurodesis including; poor performance of pleurodesis,
the presence of a massive effusion in the chest radiography and
the existence of concomitant radiographic abnormalities
showed a signiﬁcant association with a low probability of re-
sponse to pleurodesis, perhaps reﬂecting a more extensive tu-
mor spread [25].
Morrison et al.[27] reported that sclerotherapy failed in pa-
tients who had sclerosis performed when drainage from their
chest tube was more than 100 ml/day.
The impact of repeated thoracentesis 397In patients with low-pH effusions, the visceral pleura is
trapped by tumor and collagen, and the lung cannot expand
to the chest wall; and the normal pleura is replaced by tumor
and collagen and the sclerosing agent doesn’t induce the same
ﬁbrotic response as it does with normally exposed mesothelium
[28].
Danby et al. [29] noted that all failures in their study were
lung cancer patients and in some patients, the lung may be-
come trapped by tumor or ﬁbrin, a condition that commonly
leads to pleurodesis failure.Conclusion
Repeated thoracentesis may be of considerable value in pre-
dicting the success of subsequent chemical pleurodesis in
MPE. Repeated thoracentesis of MPE >7 times before chem-
ical pleurodesis has good sensitivity (75.3% and 80.3% after 30
and 60 days of the the procedure respectively) but low speciﬁc-
ity (65.7% and 64.4% after 30 and 60 days of the procedure
respectively) in predicting success of subsequent chemical pleu-
rodesis. Measurement of PF glucose levels and PF cytology
provide information about the outcome of chemical pleurode-
sis in MPE.References
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